FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease wit ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

In a world first, Canadian scientists at the CRCHUM, the hospital research center affiliated with Université de Montréal, ...

Recent research reveals COVID-19 significantly increases long-term kidney dysfunction risk compared with influenza, ...

Queen Latifah has partnered with Novo Nordisk to bring awareness to obesity and heart health, and the seriousness behind the ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

Approximately 1 in 10 patients with lupus nephritis eventually progresses to kidney failure. Longer remission may help prevent chronic kidney disease (CKD) onset.

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...